Importation
Eight Surprising Things We Learned from Reading the 1,200 Comments Filed with the FDA on Canadian Drug Importation
For 78 days, the Department of Health and Human Services accepted public comment on the proposed rulemaking that would allow states to establish drug importation programs, individuals and organizations submitted 1,210 comments, and PSM read each of them. Here are what we feel are the most important takeaways…
[...]Executive Director of Colon Cancer Association Warns Against “Ill-Considered Drug Importation Scheme”
This editorial by Andrew Spiegel was published in The International Business Times on March 23, 2020. Mr. Spiegel is executive director of the Global Colon Cancer Association and Chair of the World Patient Alliance. President Trump, Price Controls Can’t Combat Coronavirus The U.S. outbreak of novel coronavirus, COVID-19, has quickly evolved into a national nightmare.…
[...]HHS comments come in overwhelmingly against Canadian drug importation proposal
Yesterday ended a 78-day comment period for the White House’s proposal to import medicine from Canada. In all, over 1,000 comments were filed. Overwhelmingly, these comments opposed the proposed rule or expressed skepticism that the rule could meet the two requirements listed in the Medicare Modernization Act of 2003: be safe and save consumers money. In fact, when you read the comments, it is clear that this policy is overwhelming opposed by experts on the issues of economics and medicine safety.
[...]Delaware Legislative Group Says Importation only “seems good until one understands the details.”
In January, the Delaware’s Interagency Pharmaceuticals Purchasing Study Group opined that that importation was not a viable strategy to lower prescription drug prices.
[...]Canadian drug importation is “an economic fantasy,” former Canadian health minister says.
In this editorial in The Globe and Mail, Ujjal Dosanjh, formerly a federal minister of health and a premier of British Columbia, explains that drug manufacturers have no incentive to sell Canadian provinces more medicine to fill the needs of U.S. residents. Importation will lead to drug shortages in Canada and counterfeit drug trafficking to the U.S.
[...]FDA Worked With Indian Government To Seize 500 Counterfeit Drug Shipments in January
The U.S. Food and Drug Administration (FDA) has just announced a successful joint operation with the Government of India targeting counterfeit prescription drugs, counterfeit over-the-counter medications, fake medical devices, and misbranded dietary supplements containing harmful ingredients.
[...]Canadian Importation Does Not Work
The number of U.S. residents in states that are considering importing drugs from Canada is almost four times Canada’s own population. Canadian drug importation is not the structural solution we need.
[...]PSM files comments on HHS’s proposed Canadian drug importation rules; cites danger to patients
Today The Partnership for Safe Medicines filed comments with Health and Human Services about the dangers posed by its draft regulations for state-based Canadian drug importation programs. PSM cited historic problems with and patient harm from Canadian vendors selling counterfeit medications to U.S. patients and medical practices; showed broad opposition to the plan by Canadian stakeholders; and provides alternatives that don’t impact patient safety.
[...]Security Breach Illustrates Another Danger of Fake Online Pharmacies
Planet Drugs Direct, an online pharmacy based in Winnipeg, Canada, has announced a data breach. Hackers broke into their servers, exposing customers’ names, medical details, and contact and banking information. Legitscript is unequivocal in calling Planet Drugs Direct a “Rogue Internet Pharmacy,” their worst rating for online pharmacies, accusing them of violating state and federal laws.
[...]Infographic: Counterfeiting By The Numbers
Our infographic, “Counterfeiting by the Numbers,” highlights facts from the U.S. Department of Homeland Security’s January 2020 report, Combating Trafficking in Counterfeit and Pirated Goods, which documents the extraordinary scale of the global counterfeiting market and its effects across all economic sectors—including medicines.
[...]